XTLB 2.09 XTL Biopharmaceuticals Ltd.
| Range: | 0.75-4.99 | Vol Avg: | 9203 | Last Div: | 0 | Changes: | -0.07 |
| Beta: | 0.88 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Sep 01 2005 | Empoloyees: | 8 | ||
| CUSIP: | 98386D307 | CIK: | 0001023549 | ISIN: | US98386D3070 | Country: | IL |
| CEO: | Mr. Shlomo Spokone Shalev | Website: | https://www.xtlbio.com | ||||
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow